Lead Product(s) : S-Pindolol Benzoate
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Actimed to Study S-pindolol’s Muscle-Preserving Effects in Obese GLP-1 Patients
Details : Actimed is currently preparing for further clinical studies of its lead product ACM-001.1 (S-pindolol benzoate) which is an ACTA targeting multiple pathways that drive cancer cachexia.
Product Name : ACM-001.1
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 20, 2025
Lead Product(s) : S-Pindolol Benzoate
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Foralumab,Semaglutide
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Tiziana Announces Success in Ozempic and Nasal Anti-CD3 Combination Study
Details : Anti-CD3 antibody TZLS-401 (foralumab) in combination with semaglutide, a GLP-1 agonist is being investigated for obesity.
Product Name : TZLS-401
Product Type : Antibody
Upfront Cash : Inapplicable
October 30, 2024
Lead Product(s) : Foralumab,Semaglutide
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Oxprenolol
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : ACM-002 (S-oxprenolol) is the second in a new class of anabolic-catabolic transforming agents (ACTAs) under development by Actimed. The new patent contains claims which cover the treatment of the symptoms of cachexia in patients having a late stage cance...
Product Name : ACM-002
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 12, 2020
Lead Product(s) : Oxprenolol
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable